EFFICACY AND SAFETY OF SGLT2 INHIBITORS IN POST-ACUTE MYOCARDIAL INFARCTION PATIENTS: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.31435/ijitss.4(52).2026.6864Keywords:
Acute Myocardial Infarction, SGLT2 Inhibitors, Left Ventricular Remodeling, Heart Failure HospitalizationAbstract
Background: Preventing adverse left ventricular remodeling and heart failure (HF) remains a key challenge after acute myocardial infarction (AMI). This systematic review evaluated the efficacy and safety of early SGLT2 inhibitor initiation in patients with AMI.
Aim: To systematically evaluate the clinical efficacy and safety of SGLT2 inhibitors initiated early after AMI, focusing on heart failure outcomes, mortality, echocardiographic markers of ventricular remodeling, and treatment-related adverse events
Materials and methods: A systematic PubMed search identified 30 eligible studies (including 24 randomized controlled trials and post-hoc analyses) that evaluated SGLT2 inhibitors versus placebo or standard care in adults post-AMI patients. Key outcomes included mortality, HF hospitalizations, echocardiographic parameters, and adverse events
Results: SGLT2 inhibitors (predominantly empagliflozin 10 mg or dapagliflozin 10 mg daily) were typically initiated within 72 h to 14 days post-MI. While all-cause mortality was comparable to that of placebo across the included studies, SGLT2 inhibitors significantly reduced HF-related endpoints. Landmark evidence (EMPACT-MI) demonstrated a 22% reduction in first HF hospitalization or HF death (HR 0.78; 95% CI 0.62–0.98; P=0.031) and a 31% reduction in total cumulative HF events (RR 0.69; 95% CI 0.51–0.93; P=0.015), irrespective of baseline diabetes or chronic kidney disease status. Most trials also showed favorable impacts on left ventricular remodeling parameters (LVEF and GLS). The therapy exhibited high tolerability, with severe adverse events (ketoacidosis, hypoglycemia, and renal impairment) occurring in <0.1% of patients, similar to the placebo.
Conclusion: Early post-AMI initiation of SGLT2 inhibitors is safe and significantly mitigates the risk of HF hospitalization and cumulative adverse cardiac events, supporting their integration into post-infarction therapeutic regimens.
References
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Jüni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-3826. https://doi.org/10.1093/eurheartj/ehad191. Erratum in: Eur Heart J. 2024 Apr 1;45(13):1145. https://doi.org/10.1093/eurheartj/ehad870 PMID: 37622654.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. https://doi.org/10.1093/eurheartj/ehab368 Erratum in: Eur Heart J. 2021 Dec 21;42(48):4901. https://doi.org/10.1093/eurheartj/ehab670. PMID: 34447992.
Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol. 2020 Dec;17(12):773-789. https://doi.org/10.1038/s41569-020-0403-y Epub 2020 Jul 3. PMID: 32620851..
Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020 Dec;17(12):761-772. https://doi.org/10.1038/s41569-020-0406-8 Epub 2020 Jul 14. PMID: 32665641.
Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 Oct;16(10):556-577. https://doi.org/10.1038/s41574-020-0392-2 Epub 2020 Aug 27. PMID: 32855502.
Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020 Jun 22;5(6):632-644. https://doi.org/10.1016/j.jacbts.2020.02.004 PMID: 32613148; PMCID: PMC7315190.
Tavecchia GA, Gualini E, Sacco A, Oliva F. The role of sodium-glucose co-transporter 2 inhibitors in myocardial infarction: available evidence and future perspectives. Eur Heart J Suppl. 2024 Apr 17;26(Suppl 1):i84-i87. https://doi.org/10.1093/eurheartjsupp/suae008 PMID: 38867868; PMCID: PMC11167973.
Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, Mattheus M, Zwiener I, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chen Y, Chopra VK, Figtree G, Ge J, Goodman SG, Gotcheva N, Goto S, Gasior T, Jamal W, Januzzi JL, Jeong MH, Lopatin Y, Lopes RD, Merkely B, Parikh PB, Parkhomenko A, Ponikowski P, Rossello X, Schou M, Simic D, Steg PG, Szachniewicz J, van der Meer P, Vinereanu D, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF. Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024 Apr 25;390(16):1455-1466. https://doi.org/10.1056/NEJMoa2314051 Epub 2024 Apr 6. PMID: 38587237.
James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, Andersen K, Austin D, Arefalk G, Carrick D, Hofmann R, Hoole SP, Jones DA, Lee K, Tygesen H, Johansson PA, Langkilde AM, Ridderstråle W, Parvaresh Rizi E, Deanfield J, Oldgren J. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evid. 2024 Feb;3(2):EVIDoa2300286. https://doi.org/10.1056/EVIDoa2300286 Epub 2023 Nov 11. PMID: 38320489.
von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, Alber H, Berger R, Lichtenauer M, Saely CH, Moertl D, Auersperg P, Reiter C, Rieder T, Siller-Matula JM, Gager GM, Hasun M, Weidinger F, Pieber TR, Zechner PM, Herrmann M, Zirlik A, Holman RR, Oulhaj A, Sourij H. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022 Nov 1;43(41):4421-4432. https://doi.org/10.1093/eurheartj/ehac494 PMID: 36036746; PMCID: PMC9622301.
Hernandez AF, Udell JA, Jones WS, Anker SD, Petrie MC, Harrington J, Mattheus M, Seide S, Zwiener I, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chen Y, Chopra VK, A Figtree G, Ge J, G Goodman S, Gotcheva N, Goto S, Gasior T, Jamal W, Januzzi JL, Jeong MH, Lopatin Y, Lopes RD, Merkely B, Parikh PB, Parkhomenko A, Ponikowski P, Rossello X, Schou M, Simic D, Steg PG, Szachniewicz J, van der Meer P, Vinereanu D, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Butler J. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. Circulation. 2024 May 21;149(21):1627-1638. https://doi.org/10.1161/CIRCULATIONAHA.124.069217 Epub 2024 Apr 6. PMID: 38581389; PMCID: PMC11115458.
Erlinge D, James S, Deanfield J, Eriksson N, de Belder M, Alchay M, Austin D, Jones DA, Ravn-Fischer A, Sederholm Lawesson S, Shah N, Strange JW, Szummer K, Ridderstråle W, Parvaresh Rizi E, Langkilde AM, Johansson PA, McGuire DK, Oldgren J, Storey RF. Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI. ESC Heart Fail. 2025 Dec;12(6):4184-4193. https://doi.org/10.1002/ehf2.15420 Epub 2025 Sep 16. PMID: 40958495; PMCID: PMC12719873.
Fioretti F, Butler J, Udell JA, Schuyler Jones W, Petrie MC, Harrington J, Mattheus M, Bauersachs J, Bayes-Genis A, Goodman SG, Gasior T, Januzzi JL, Lopes RD, Ponikowski P, Rossello X, Schou M, van der Meer P, Vinereanu D, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF, Anker SD. Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI. ESC Heart Fail. 2025 Dec;12(6):3940-3952. https://doi.org/10.1002/ehf2.15393 Epub 2025 Sep 14. PMID: 40947857; PMCID: PMC12719805.
Carberry J, Petrie MC, Lee MMY, Stanley B, Brooksbank KJM, Campbell RT, Good R, Jhund PS, Kellman P, Lang NN, Lindsay MM, Mangion K, Gardner RS, Mark PB, Meyer B, O'Donnell J, Orchard V, Shaukat A, Watkins S, McConnachie A, McMurray JJV, Welsh P, Sattar N, Berry C, Docherty KF. Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI). Eur J Heart Fail. 2025 Mar;27(3):566-576. https://doi.org/10.1002/ejhf.3560 Epub 2024 Dec 15. PMID: 39675781; PMCID: PMC11955320.
Ortega-Paz L, Laudani C, Sionis A, Vidal-Cales P, Arevalos V, Andrea R, Morr CI, De Diego O, Ortega E, Jimenez-Trinidad FR, Dantas AP, Angiolillo DJ, Sabaté M, Ortiz-Pérez JT, Brugaletta S. Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI Trial. J Cardiovasc Dev Dis. 2025 Jun 11;12(6):220. https://doi.org/10.3390/jcdd12060220 PMID: 40558655; PMCID: PMC12194218.
Petrie MC, Udell JA, Anker SD, Harrington J, Jones WS, Mattheus M, Gasior T, van der Meer P, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chopra VK, Januzzi JL, Lopes RD, Ponikowski P, Rossello X, Schou M, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF, Butler J. Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial. Eur J Heart Fail. 2025 Mar;27(3):577-588. https://doi.org/10.1002/ejhf.3548 Epub 2024 Dec 26. PMID: 39725521; PMCID: PMC11955319.
Mozawa K, Kubota Y, Hoshika Y, Tara S, Tokita Y, Yodogawa K, Iwasaki YK, Yamamoto T, Takano H, Tsukada Y, Asai K, Miyamoto M, Miyauchi Y, Kodani E, Maruyama M, Tanabe J, Shimizu W. Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus. ESC Heart Fail. 2021 Oct;8(5):4161-4173. https://doi.org/10.1002/ehf2.13509 Epub 2021 Jul 7. PMID: 34235875; PMCID: PMC8497324.
Aggarwal R, Bhatt DL, Hernandez AF, Anker SD, Harrington J, Jones WS, Mattheus M, Petrie MC, Steubl D, Sumin M, Thanam V, Udell JA, Butler J. Secondary analysis of the EMPACT-MI trial reveals cardiovascular-kidney efficacy and safety of empagliflozin after acute myocardial infarction. Nat Cardiovasc Res. 2025 Jun;4(6):761-772. https://doi.org/10.1038/s44161-025-00657-7 Epub 2025 Jun 13. PMID: 40514435; PMCID: PMC12170341.
Sourij C, Aziz F, Tripolt NJ, Siller-Matula J, Pferschy PN, Kolesnik E, Wallner M, Eyileten C, Postula M, Oulhaj A, Sourij H, von Lewinski D; EMMY study group. Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial. Hellenic J Cardiol. 2024 Jan-Feb;75:3-8. https://doi.org/10.1016/j.hjc.2023.05.007 Epub 2023 May 24. PMID: 37236318.
Benedikt M, Mangge H, Aziz F, Curcic P, Pailer S, Herrmann M, Kolesnik E, Tripolt NJ, Pferschy PN, Wallner M, Zirlik A, Sourij H, von Lewinski D. Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial. Cardiovasc Diabetol. 2023 Jul 5;22(1):166. https://doi.org/10.1186/s12933-023-01904-6 PMID: 37407956; PMCID: PMC10324245.
Khani E, Aslanabadi N, Mehravani K, Rezaei H, Afsharirad H, Entezari-Maleki T. Empagliflozin Effects in Patients with ST-Elevation Myocardial Infarction Undergoing Primary PCI: The EMI-STEMI Randomized Clinical Trial. Am J Cardiovasc Drugs. 2024 Sep;24(5):673-684. https://doi.org/10.1007/s40256-024-00662-4 Epub 2024 Jul 5. PMID: 38969953.
Dayem KA, Younis O, Zarif B, Attia S, AbdelSalam A. Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients - DACAMI (a randomized controlled clinical trial). Int J Cardiol. 2023 May 15;379:9-14. https://doi.org/10.1016/j.ijcard.2023.03.002 Epub 2023 Mar 6. PMID: 36889650
Sourij C, Aziz F, Tripolt NJ, Siller-Matula J, Pferschy PN, Kolesnik E, Wallner M, Eyileten C, Postula M, Oulhaj A, Sourij H, von Lewinski D; EMMY study group. Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial. Hellenic J Cardiol. 2024 Jan-Feb;75:3-8. https://doi.org/10.1016/j.hjc.2023.05.007 Epub 2023 May 24. PMID: 37236318.
Baharvand F, Mehran R, Di Muro FM, Mohammadi A, Aghajankhah M, Parvaneh S, Parsa NA, Hassanipour S, Aboutaleb E, Jenab Y, Aliabadi SB. Empagliflozin in STEMI Patients: A Randomized Controlled Trial on Left Ventricular Recovery and Cardiovascular Outcomes. Am J Cardiovasc Drugs. 2026 Jul 17. https://doi.org/10.1007/s40256-026-00814-8 Epub ahead of print. PMID: 42467386.
Shimizu W, Kubota Y, Hoshika Y, Mozawa K, Tara S, Tokita Y, Yodogawa K, Iwasaki YK, Yamamoto T, Takano H, Tsukada Y, Asai K, Miyamoto M, Miyauchi Y, Kodani E, Ishikawa M, Maruyama M, Ogano M, Tanabe J; EMBODY trial investigators. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol. 2020 Sep 25;19(1):148. https://doi.org/10.1186/s12933-020-01127-z PMID: 32977831; PMCID: PMC7519555.
Tripolt NJ, Kolesnik E, Pferschy PN, Verheyen N, Ablasser K, Sailer S, Alber H, Berger R, Kaulfersch C, Leitner K, Lichtenauer M, Mader A, Moertl D, Oulhaj A, Reiter C, Rieder T, Saely CH, Siller-Matula J, Weidinger F, Zechner PM, von Lewinski D, Sourij H; EMMY study group. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial. Am Heart J. 2020 Mar;221:39-47. https://doi.org/10.1016/j.ahj.2019.12.004 Epub 2019 Dec 12. PMID: 31901799. [20]
Afsharirad H, Ghaffari S, Javanshir E, Allord S, Khani E, Entezari-Maleki T. Dapagliflozin Effects in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The DAPA-STEMI Randomized Clinical Trial. Am J Ther. 2026 Jul-Aug 01;33(4):e292-e301. https://doi.org/10.1097/MJT.0000000000002077 Epub 2026 Feb 19. PMID: 41711508.
Macías-Cervantes HE, Guardado-Mendoza R, González LJ, Bautista-López GR, Hernández-Tizapa K, Carrillo-Torres MÁ, Fernández-Yáñez G, Hinojosa-Gutiérrez LR, Bernal-Ruiz EA, Cárdenas-Muñoz ME, Nava-Cabrera JI, Caporal-Trejo LC, Emigdio-Loeza A, Hernández-González MA, Macías-Cervantes MH. Dapagliflozin in acute myocardial infarction with type 2 diabetes: a randomized clinical trial. Curr Probl Cardiol. 2026 Jul 18;51(10):103401. https://doi.org/10.1016/j.cpcardiol.2026.103401 Epub ahead of print. PMID: 42471097.
Daoulah A, Jamjoom A, Arafat AA, Yousif N, Almahmeed W, Arabi A, Panduranga P, Lotfi A, Abdirahman Kahin M, Aloui HM, Kanbr O, Alswuaidi J, Alamro B, Alshehri M, Alharbi W, Alzahrani B, Al Obaikan S, Alshali KZ, Alenezi A, Al Maashani S, Rajan R, Qutub MA, Balghith M, Hassan T, Alqahtani AM, Abdulhabeeb IAM, Ghani MA, Fathey Hussien A, Shawky AM, Elmahrouk Y, Seraj S, Elmahrouk A. Sodium-Glucose Cotransporter 2 Inhibitors as Discharge Medications in Survivors of Acute Myocardial Infarction Complicated by Cardiogenic Shock. Shock. 2026 Jun 30. https://doi.org/10.1097/SHK.0000000000002904 Epub ahead of print. PMID: 42380740.
Deng L, Wang J, Deng Y, Huang J, Gu Q, Chen Q, Pan L, Wei J, Wang Q, Sun L. Effect of dapagliflozin on malignant ventricular arrhythmias in elderly after acute myocardial infarction: a propensity score-matched cohort study. Eur J Clin Pharmacol. 2025 Jun;81(6):839-851. https://doi.org/10.1007/s00228-025-03832-8 Epub 2025 Apr 1. PMID: 40167624.
Jiang Y, Jia S, Tian D, Qiang H, Zhao H, Chen X, Su X, Jia X. Association of In-Hospital Dapagliflozin Initiation with Favorable left Ventricular Remodeling in Patients with Acute Myocardial Infarction and Heart Failure: A Retrospective Cohort Study. Cardiovasc Drugs Ther. 2026 Jul 1. https://doi.org/10.1007/s10557-026-07904-4 Epub ahead of print. PMID: 42384323.
Chen J, Chang J, Shi Q, Li X, Wang L, Zhao H. Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study. BMC Cardiovasc Disord. 2023 Oct 7;23(1):495. https://doi.org/10.1186/s12872-023-03542-y PMID: 37805494; PMCID: PMC10559512.
Adel SMH, Jorfi F, Mombeini H, Rashidi H, Fazeli S. Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention. Saudi Med J. 2022 May;43(5):458-464. https://doi.org/10.15537/smj.2022.43.5.20220018 PMID: 35537720; PMCID: PMC9280595.
Salem HSE, El-Mawardy RM, Zahran ME, Bastawy IM, Aziz MF, Attia AE. Early Dapagliflozin in Non-diabetic Acute Myocardial Infarction Patients Post-PCI: Effects on Cardiovascular Outcomes and Left Ventricular Remodeling (EARLY DAPA-AMI). J Saudi Heart Assoc. 2025 Oct 31;37(4):9. https://doi.org/10.37616/2212-5043.1464 PMID: 41847669; PMCID: PMC12991818.
Schwegel N, Strohhofer C, Kolesnik E, Oltean S, Hüttmair A, Pipp C, Benedikt M, Verheyen N, Gollmer J, Ablasser K, Wallner M, Santner V, Tripolt N, Pferschy P, Zechner P, Alber H, Siller-Matula JM, Kopp K, Zirlik A, Aziz F, Sourij H, von Lewinski D. Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial. Clin Res Cardiol. 2025 May;114(5):629-639. https://doi.org/10.1007/s00392-024-02523-1 Epub 2024 Sep 16. PMID: 39297940; PMCID: PMC12058928.
Quach HT, Nguyen ATK, Dinh BQ, Nguyen TM, Bui HH, Tran TN, Ho TD, Pham AL, Nguyen SV. Favorable association between early initiation of sodium-glucose cotransporter-2 inhibitors and in-hospital prognosis in acute myocardial infarction. PLoS One. 2026 Mar 27;21(3):e0345315. https://doi.org/10.1371/journal.pone.0345315PMID: 41894348; PMCID: PMC13028360.
Hoshika Y, Kubota Y, Mozawa K, Tara S, Tokita Y, Yodogawa K, Iwasaki YK, Yamamoto T, Takano H, Tsukada Y, Asai K, Miyamoto M, Miyauchi Y, Kodani E, Maruyama M, Tanabe J, Shimizu W. Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus. Diabetes Ther. 2021 Aug;12(8):2241-2248. https://doi.org/10.1007/s13300-021-01103-0 Epub 2021 Jul 8. PMID: 34236577; PMCID: PMC8342682.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Jakub Sokołowski, Kalina Światlak, Justyna Trzaskalik, Wiktoria Żelazna, Monika Leśniak

This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.

